About Enhancer

Enhancer ID: E_01_0550
Species: human
Position : chr8:127732161-127734161
Biosample name:
Experiment class : High+Lowthroughput
Enhancer type: Enhancer
Disease: Osteosarcoma
Pubmed ID:  29644114
Enhancer experiment: ChIP-seq,Immunohistochemistry,western blot,High throughput RNA seq,MTS assay,
Enhancer experiment description: THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.

About Target gene

Target gene : CDK6,RECQL4,WRN,BLM
Strong evidence: qRT-PCR,qPCR,ChIP,3C
Less strong evidence: RNA-Seq
Target gene experiment description: THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.

About TF

TF name : MYC(MRTLC,bHLHe39,c-Myc,MYC)TGFB2TP53(BCC7,BMFS5,LFS1,P53,TRP53)RB1BRD4(CAP,HUNK1,HUNKI,MCAP)
TF experiment: ChIP-seq,Immunohistochemistry,western blot,High throughput RNA seq,MTS assay,
TF experiment description: THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.;THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.

About Function

Enhancer function : THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.
Enhancer function experiment: Immunohistochemical staining
Enhancer function
experiment description:		 THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.

About SNP

SNP ID: --

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
MYC AP-1 transcription factor network pid 71
MYC Binding of TCF/LEF:CTNNB1 to target gene promoters reactome 7
MYC C-MYB transcription factor network pid 87
MYC C-MYC pathway pid 25
MYC CD40/CD40L signaling pid 36
MYC Ceramide signaling pathway pid 49
MYC Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants reactome 57
MYC Constitutive Signaling by NOTCH1 PEST Domain Mutants reactome 57
MYC Cyclin A:Cdk2-associated events at S phase entry reactome 15
MYC Cyclin E associated events during G1/S transition reactome 14
MYC E2F transcription factor network pid 77
MYC EGFR1 netpath 475
MYC Formation of the beta-catenin:TCF transactivating complex reactome 88
MYC FOXM1 transcription factor network pid 43
MYC IL2-mediated signaling events pid 54
MYC IL2 signaling events mediated by PI3K pid 38
MYC IL2 signaling events mediated by STAT5 pid 30
MYC IL6-mediated signaling events pid 48
MYC Interleukin signaling pathway panther 86
MYC LKB1 signaling events pid 43
MYC MAPK6/MAPK4 signaling reactome 90
MYC Notch signaling pathway pid 58
MYC NOTCH1 Intracellular Domain Regulates Transcription reactome 47
MYC Oxidative stress response panther 23
MYC p53 pathway feedback loops 2 panther 42
MYC p73 transcription factor network pid 80
MYC PDGF signaling pathway panther 113
MYC PDGFR-beta signaling pathway pid 125
MYC Presenilin action in Notch and Wnt signaling pid 46
MYC Prolactin netpath 105
MYC Regulation of nuclear beta catenin signaling and target gene transcription pid 80
MYC Regulation of nuclear SMAD2/3 signaling pid 82
MYC Regulation of Telomerase pid 70
MYC SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription reactome 32
MYC TGF_beta_Receptor netpath 220
MYC Validated nuclear estrogen receptor alpha network pid 65
MYC Validated targets of C-MYC transcriptional activation pid 80
MYC Validated targets of C-MYC transcriptional repression pid 63
MYC MAPK signaling pathway kegg 264
MYC ErbB signaling pathway kegg 83
MYC Cell cycle kegg 124
MYC Wnt signaling pathway kegg 135
MYC TGF-beta signaling pathway kegg 82
MYC Jak-STAT signaling pathway kegg 149
MYC Pathways in cancer kegg 321
MYC Colorectal cancer kegg 63
MYC Endometrial cancer kegg 52
MYC Thyroid cancer kegg 25
MYC Bladder cancer kegg 38
MYC Chronic myeloid leukemia kegg 69
MYC Acute myeloid leukemia kegg 53
MYC Small cell lung cancer kegg 83
MYC Hs_DNA_Damage_Response_(only_ATM_dependent)_WP710_79974 wikipathways 36
MYC Hs_TP53_Network_WP1742_71700 wikipathways 10
MYC Hs_Imatinib_and_Chronic_Myeloid_Leukemia_WP3640_89384 wikipathways 11
MYC Hs_miRNAs_involved_in_DNA_damage_response_WP1545_84697 wikipathways 30
MYC Hs_Association_Between_Physico-Chemical_Features_and_Toxicity_Associated_Pathways_WP3680_90113 wikipathways 31
MYC Hs_Gastric_Cancer_Network_2_WP2363_87523 wikipathways 28
MYC Hs_Hepatitis_C_and_Hepatocellular_Carcinoma_WP3646_88640 wikipathways 36
MYC Hs_Apoptosis_WP254_88977 wikipathways 31
MYC Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122
MYC Hs_Neural_Crest_Differentiation_WP2064_79263 wikipathways 40
MYC Hs_IL-5_Signaling_Pathway_WP127_78498 wikipathways 35
MYC Hs_Prolactin_Signaling_Pathway_WP2037_90015 wikipathways 52
MYC Hs_EGF-EGFR_Signaling_Pathway_WP437_79266 wikipathways 107
MYC Hs_IL-7_Signaling_Pathway_WP205_89854 wikipathways 16
TGFB2 ATF-2 transcription factor network pid 59
TGFB2 ECM proteoglycans reactome 55
TGFB2 Heterotrimeric GPCR signaling pathway (through G alpha i and pertussis toxin) ( GPCR signaling (pertussis toxin) ) inoh 228
TGFB2 Heterotrimeric GPCR signaling pathway (through G alpha q, PLC beta and ERK cascade) ( GPCR signaling (G alpha q) ) inoh 239
TGFB2 Heterotrimeric GPCR signaling pathway (through G alpha s ACs Epac BRaf and ERKcascade) ( GPCR signaling (G alpha s, Epac and ERK) ) inoh 237
TGFB2 Heterotrimeric GPCR signaling pathway (through_G alpha s_ACs_PKA_BRaf_and_ERKcascade)(canonical) ( GPCR signaling (G alpha s, PKA and ERK) ) inoh 227
TGFB2 Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through G alpha i, adenylate cyclase and cAMP) ( GPCR signaling (G alpha i) ) inoh 228
TGFB2 Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through_G_alpha_s,_cholera_toxin,_adenylate_cyclase_and_cAMP) ( GPCR signaling (cholera toxin) ) inoh 227
TGFB2 Molecules associated with elastic fibres reactome 30
TGFB2 Platelet degranulation reactome 107
TGFB2 Regulation of retinoblastoma protein pid 67
TGFB2 Signaling events mediated by the Hedgehog family pid 24
TGFB2 TGF-beta signaling pathway panther 88
TGFB2 TGF-beta_super_family_signaling_pathway(canonical) ( TGF-beta_BMP Diagram(MolecularVariation) ) inoh 51
TGFB2 TGF beta signaling pathway(through TAK1) ( TGF-beta signaling(through TAK1) ) inoh 8
TGFB2 TGF_beta_Receptor netpath 220
TGFB2 MAPK signaling pathway kegg 264
TGFB2 Cytokine-cytokine receptor interaction kegg 213
TGFB2 Cell cycle kegg 124
TGFB2 Endocytosis kegg 201
TGFB2 TGF-beta signaling pathway kegg 82
TGFB2 Leishmaniasis kegg 71
TGFB2 Chagas disease kegg 103
TGFB2 Malaria kegg 50
TGFB2 Toxoplasmosis kegg 131
TGFB2 Amoebiasis kegg 103
TGFB2 Pathways in cancer kegg 321
TGFB2 Colorectal cancer kegg 63
TGFB2 Renal cell carcinoma kegg 65
TGFB2 Pancreatic cancer kegg 70
TGFB2 Chronic myeloid leukemia kegg 69
TGFB2 Hypertrophic cardiomyopathy (HCM) kegg 78
TGFB2 Dilated cardiomyopathy kegg 85
TP53 Activation of PUMA and translocation to mitochondria reactome 8
TP53 AP-1 transcription factor network pid 71
TP53 Apoptosis signaling pathway panther 104
TP53 Association of TriC/CCT with target proteins during biosynthesis reactome 39
TP53 Aurora A signaling pid 33
TP53 Autodegradation of the E3 ubiquitin ligase COP1 reactome 51
TP53 BARD1 signaling events pid 29
TP53 Direct p53 effectors pid 141
TP53 DNA Damage/Telomere Stress Induced Senescence reactome 64
TP53 EGFR1 netpath 475
TP53 Factors involved in megakaryocyte development and platelet production reactome 111
TP53 Formation of Senescence-Associated Heterochromatin Foci (SAHF) reactome 17
TP53 G2/M Checkpoints reactome 50
TP53 G2/M DNA damage checkpoint reactome 84
TP53 Glucocorticoid receptor regulatory network pid 85
TP53 Huntington disease panther 113
TP53 Hypoxic and oxygen homeostasis regulation of HIF-1-alpha pid 19
TP53 LKB1 signaling events pid 43
TP53 Oncogene Induced Senescence reactome 30
TP53 Oxidative Stress Induced Senescence reactome 120
TP53 p53 pathway by glucose deprivation panther 21
TP53 p53 pathway panther 39
TP53 p53 pathway pid 59
TP53 P53 pathway feedback loops 1 panther 6
TP53 p53 pathway feedback loops 2 panther 42
TP53 p75(NTR)-mediated signaling pid 74
TP53 PLK3 signaling events pid 6
TP53 Pre-NOTCH Transcription and Translation reactome 29
TP53 Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks reactome 75
TP53 Regulation of TP53 Activity through Acetylation reactome 23
TP53 Regulation of TP53 Activity through Association with Co-factors reactome 14
TP53 Regulation of TP53 Activity through Methylation reactome 19
TP53 Regulation of TP53 Activity through Phosphorylation reactome 89
TP53 Regulation of TP53 Degradation reactome 35
TP53 Signaling events mediated by HDAC Class III pid 41
TP53 Signaling mediated by p38-alpha and p38-beta pid 35
TP53 Stabilization of p53 reactome 9
TP53 SUMOylation of transcription factors reactome 14
TP53 TGF_beta_Receptor netpath 220
TP53 The role of GTSE1 in G2/M progression after G2 checkpoint reactome 59
TP53 TNFalpha netpath 274
TP53 TP53 Regulates Metabolic Genes reactome 85
TP53 TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain reactome 21
TP53 TP53 Regulates Transcription of Caspase Activators and Caspases reactome 12
TP53 TP53 Regulates Transcription of Death Receptors and Ligands reactome 12
TP53 TP53 Regulates Transcription of DNA Repair Genes reactome 61
TP53 TP53 Regulates Transcription of Genes Involved in Cytochrome C Release reactome 19
TP53 TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest reactome 13
TP53 TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest reactome 18
TP53 TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain reactome 14
TP53 Validated targets of C-MYC transcriptional activation pid 80
TP53 Vinblastine Action Pathway smpdb 11
TP53 Vincristine Action Pathway smpdb 10
TP53 Vindesine Action Pathway smpdb 10
TP53 Vinorelbine Action Pathway smpdb 11
TP53 MAPK signaling pathway kegg 264
TP53 Cell cycle kegg 124
TP53 p53 signaling pathway kegg 66
TP53 Apoptosis kegg 88
TP53 Wnt signaling pathway kegg 135
TP53 Neurotrophin signaling pathway kegg 126
TP53 Amyotrophic lateral sclerosis (ALS) kegg 53
TP53 Huntington's disease kegg 182
TP53 Hepatitis C kegg 134
TP53 Pathways in cancer kegg 321
TP53 Colorectal cancer kegg 63
TP53 Pancreatic cancer kegg 70
TP53 Endometrial cancer kegg 52
TP53 Glioma kegg 65
TP53 Prostate cancer kegg 85
TP53 Thyroid cancer kegg 25
TP53 Basal cell carcinoma kegg 51
TP53 Melanoma kegg 69
TP53 Bladder cancer kegg 38
TP53 Chronic myeloid leukemia kegg 69
TP53 Small cell lung cancer kegg 83
TP53 Non-small cell lung cancer kegg 54
TP53 Hs_Cell_Cycle_WP179_89516 wikipathways 33
TP53 Hs_Tryptophan_metabolism_WP465_85055 wikipathways 45
TP53 Hs_ErbB_Signaling_Pathway_WP673_91869 wikipathways 37
TP53 Hs_DNA_Damage_Response_(only_ATM_dependent)_WP710_79974 wikipathways 36
TP53 Hs_TP53_Network_WP1742_71700 wikipathways 10
TP53 Hs_DNA_Damage_Response_WP707_82937 wikipathways 28
TP53 Hs_miRNA_Regulation_of_DNA_Damage_Response_WP1530_84694 wikipathways 28
TP53 Hs_Nuclear_Receptors_in_Lipid_Metabolism_and_Toxicity_WP299_89331 wikipathways 10
TP53 Hs_Gastric_Cancer_Network_2_WP2363_87523 wikipathways 28
TP53 Hs_Hepatitis_C_and_Hepatocellular_Carcinoma_WP3646_88640 wikipathways 36
TP53 Hs_Senescence_and_Autophagy_in_Cancer_WP615_81193 wikipathways 62
TP53 Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122
TP53 Hs_Apoptosis_Modulation_and_Signaling_WP1772_91293 wikipathways 71
TP53 Hs_Alzheimers_Disease_WP2059_87372 wikipathways 24
TP53 Hs_Copper_homeostasis_WP3286_89205 wikipathways 15
TP53 Hs_Integrated_Cancer_Pathway_WP1971_82939 wikipathways 33
TP53 Hs_ATM_Signaling_Pathway_WP2516_90247 wikipathways 32
TP53 Hs_DNA_IR-Double_Strand_Breaks_(DSBs)_and_cellular_response_via_ATM_WP3959_91367 wikipathways 50
TP53 Hs_Pathways_Affected_in_Adenoid_Cystic_Carcinoma_WP3651_89271 wikipathways 27
TP53 Hs_LncRNA-mediated_mechanisms_of_therapeutic_resistance_WP3672_87395 wikipathways 9
TP53 Hs_Bladder_Cancer_WP2828_89143 wikipathways 17
TP53 Hs_Signaling_Pathways_in_Glioblastoma_WP2261_89520 wikipathways 16
TP53 Hs_Steroid_Biosynthesis_WP496_69016 wikipathways 8
TP53 Hs_Retinoblastoma_(RB)_in_Cancer_WP2446_87639 wikipathways 5
TP53 Hs_G1_to_S_cell_cycle_control_WP45_80001 wikipathways 8
RB1 AndrogenReceptor netpath 167
RB1 ATF-2 transcription factor network pid 59
RB1 BCR netpath 161
RB1 Ceramide signaling pathway pid 49
RB1 Condensation of Prophase Chromosomes reactome 72
RB1 Cyclin A:Cdk2-associated events at S phase entry reactome 15
RB1 Cyclin D associated events in G1 reactome 38
RB1 Cyclin E associated events during G1/S transition reactome 14
RB1 Direct p53 effectors pid 141
RB1 E2F transcription factor network pid 77
RB1 Formation of Senescence-Associated Heterochromatin Foci (SAHF) reactome 17
RB1 FOXM1 transcription factor network pid 43
RB1 ID netpath 38
RB1 IL1 netpath 69
RB1 IL3 netpath 84
RB1 IL6 netpath 85
RB1 Inhibition of replication initiation of damaged DNA by RB1/E2F1 reactome 12
RB1 Notch-mediated HES/HEY network pid 48
RB1 Orc1 removal from chromatin reactome 70
RB1 p53 pathway feedback loops 2 panther 42
RB1 p73 transcription factor network pid 80
RB1 Prolactin netpath 105
RB1 Regulation of retinoblastoma protein pid 67
RB1 TGF_beta_Receptor netpath 220
RB1 TNFalpha netpath 274
RB1 TSH netpath 82
RB1 Cell cycle kegg 124
RB1 Pathways in cancer kegg 321
RB1 Pancreatic cancer kegg 70
RB1 Glioma kegg 65
RB1 Prostate cancer kegg 85
RB1 Melanoma kegg 69
RB1 Bladder cancer kegg 38
RB1 Chronic myeloid leukemia kegg 69
RB1 Small cell lung cancer kegg 83
RB1 Non-small cell lung cancer kegg 54
RB1 Hs_Thyroid_Stimulating_Hormone_(TSH)_signaling_pathway_WP2032_89823 wikipathways 28
RB1 Hs_MAPK_Signaling_Pathway_WP382_79951 wikipathways 58
RB1 Hs_Leptin_and_adiponectin_WP3934_90768 wikipathways 5
RB1 Hs_Senescence_and_Autophagy_in_Cancer_WP615_81193 wikipathways 62
RB1 Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122
RB1 Hs_Integrated_Cancer_Pathway_WP1971_82939 wikipathways 33
RB1 Hs_Bladder_Cancer_WP2828_89143 wikipathways 17
RB1 Hs_Signaling_Pathways_in_Glioblastoma_WP2261_89520 wikipathways 16
RB1 Hs_Aryl_Hydrocarbon_Receptor_WP2586_91687 wikipathways 16
RB1 Hs_Retinoblastoma_(RB)_in_Cancer_WP2446_87639 wikipathways 5

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer

Enhancer associated SNPs